Urology

Erectile Dysfunction

Erectile dysfunction in Diabetics or after Prostate cancer treatment is very common and debilitating to many men. The prevalence of erectile dysfunction in diabetes overall is about 52.5% and up to 66.3% prevalence in type II diabetics. Put in another way, diabetic men are 3.5 times more likely to experience ED than non-diabetics. Erectile dysfunction after prostate cancer treatment is especially difficult to treat.

Fortunately, there are a few regenerative medical treatment options that can be tried. Here at Phenicell we offer Autologous BMAC, Umbilical cord stem cells, Exosomes. Below, I have listed a few medical references which are supportive. Remember, these treatments are not yet FDA approved, and medical insurance does not cover the cost. Furthermore, in the spirt of transparency and honesty, we cannot offer any guarantees, just that we will try our best if you are interested. We offer intracavernosal injections directly into the sides of the penis. To monitory our outcomes, we use the International index of erectile function-5 (IIEF) questionnaire scale before and after treatment. This questionnaire can be found on our website or the internet.

Contact our Phenicell Regenerative Institute for a consultation. We look forward to assisting you.

References:
a. Kouidrat Y, Pizzol D, Cosco et al.: High prevalence of erectile dysfunction in diabetes: a systematic review and meta-analysis of 145 studies. Diabet Med. 2017 Sep;34(9):1185-1192.
b. Yiou R.: Stem-cell therapy for erectile dysfunction. Biomed Mater Eng. 2017;28(s1): S81-S85.
c. Jong Yoon Bahk, Jae Hun Jung, Hoon Han, Seung Ki Min, Youn Soo Lee. Treatment of Diabetic Impotence with Umbilical Cord Blood Stem Cell Intracavernosal Transplant: Preliminary Report of 7 Cases. Exp Clin Transplant 2010. Jun. (8)2 150-60
d. R El Osta , V Decot , D Bensoussan , J F Stoltz , P Eschwege , J Hubert Treatment by stem cell therapy of erectile dysfunction of diabetic origin: State of the art [Article in French] Prog Urol. 2018 Feb;28(2):74-84.

Lupus Nephritis

Lupus can attack the kidneys. Mesenchymal stem cells derived from umbilical cord blood also helped lupus nephritis in several research papers (refs 1-4).
In patients with lupus nephritis treated with MSCs from umbilical cord blood showed to varying degrees of improvement for several months:
Decrease in 24-hour proteinuria
Decreased serum creatinine and urea nitrogen
Decreased Serum antinuclear antibody and anti-double-stranded DNA antibody
In addition, increased serum levels of albumin and complement 3 which are good. Patient may need more than one treatment.
In addition, increased serum levels of albumin and complement 3 which are good. Patient may need more than one treatment.
Here at Phenicell Regenerative Institute, we are honored to treat and study patients with SLE using this new and exciting treatment.

Contact our Phenicell Regenerative Institute for a consultation. We look forward to assisting you.

References:
1.) Sattwika PD, Mustafa R, Paramaiswari A, Herningtyas EH. Stem cells for lupus nephritis: a concise review of current knowledge. Lupus. 2018 Oct;27(12):1881-1897.
2.) Liu S, Guo YL, Yang JY, Wang W, Xu J. [Efficacy of mesenchymal stem cells on systemic lupus erythematosus:a meta-analysis]. Beijing Da Xue Xue Bao Yi Xue Ban. 2018 Dec 18;50(6):1014-1021.
3.) Liang J, Sun L. Mesenchymal stem cells transplantation for systemic lupus erythematosus. Int J Rheum Dis. 2015 Feb;18(2):164-71.
4.) Wang D, Li J, Zhang Y, Zhang M, Chen J, Li X, Hu X, Jiang S, Shi S, Sun L. Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study. Arthritis Res Ther. 2014 Mar 25;16(2):R79.